OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.725
-0.045 (-2.54%)
Nov 20, 2024, 4:00 PM EST - Market closed
OS Therapies Employees
As of December 31, 2022, OS Therapies had 4 total employees, including 3 full-time and 1 part-time employees.
Employees
4
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,854,693
Market Cap
36.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Achilles Therapeutics | 215 |
| Accelerate Diagnostics | 134 |
| Omega Therapeutics | 94 |
| Xilio Therapeutics | 73 |
| OncoCyte | 46 |
| LAVA Therapeutics | 37 |
| Gain Therapeutics | 32 |
| Reviva Pharmaceuticals Holdings | 15 |
OSTX News
- 5 days ago - OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 17 days ago - OS Therapies to Present at The Spartan Capital Investor Conference - Business Wire
- 21 days ago - Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30 - Business Wire
- 23 days ago - OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors - Business Wire
- 4 weeks ago - OS Therapies to Present at the LD Micro Main Event XVII - Business Wire
- 4 weeks ago - OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - Business Wire
- 7 weeks ago - OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit - Business Wire
- 2 months ago - OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates - Business Wire